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In this phase-I trial, we evaluated the safety of S-1, a novel oral fluoropyrimidine anticancer agent, combined with external-beam
radiotherapy (EBRT) to determine the maximum-tolerated dose and dose-limiting toxicity (DLT) in unresectable pancreatic cancer
patients. Patients had histologically proven unresectable locally advanced or metastatic pancreatic cancer. S-1 was administered orally
twice daily. External-beam radiotherapy was delivered in fractions of 1.25Gy 2 per day, totalling 50Gy per 40 fractions for 4 weeks.
S-1 was given at five dose levels: 60mgm
–2day
–1 on days 1–7 and 15–21 (level 1), 1–14 (level 2), and 1–21 (level 3a) and
80mgm
–2day
–1on days 1–21 (level 3b) and 1–28 (level 4). We studied 17 patients: dose levels 1 (four patients), 2 (four patients),
3a (three patients), 3b (three patients), and 4 (three patients). One patient in level 1 (grade 3 vomiting) and two patients in level 4
(grade 4 neutropenia and grade 3 anorexia) showed DLT. No DLT was seen for levels 2, 3a, and 3b. Clinical effects by computed
tomography included 5 partial responses (35%), 11 cases of stable disease, and one case of progressive disease. CA19–9 levels of less
than half the starting values were observed in 8 of 16 (50%) patients. S-1 at a dose of 80mgm
–2day
–1given on days 1–21 is safe
and recommended for phase-II study in patients with locally advanced and unresectable pancreatic cancer when given with EBRT.
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Adenocarcinoma of the exocrine pancreas (pancreatic cancer) is a
morbid disease with a dismal prognosis. At present, complete
surgical resection offers the best chance of cure (Yeo et al, 1995;
Takao et al, 1999). However, because of the invasion of major
vessels or the presence of metastasis, most pancreatic cancers are
already unresectable at the time of diagnosis (Niederhuber et al,
1995). Without surgical intervention, the median survival is less
than 6 months (Matsuno et al, 2004). Consequently, many studies
have recommended radiation therapy or chemotherapy as the
primary treatment for patients with unresectable pancreatic
cancers. For patients with locally unresectable disease, the results
of previous randomised trials by the Gastrointestinal Tumour
Study Group indicate that concurrent external-beam radiation
therapy (EBRT) and 5-fluorouracil (5-FU) therapy results in
significantly better survival than EBRT or chemotherapy alone
(Gastrointestinal Tumour Study Group, 1981, 1988). Since then,
concurrent EBRT and 5-FU have been generally accepted as the
standard treatment for locally advanced pancreatic cancer
(Klaassen et al, 1985; Poen et al, 1999; Paulino and Latona, 2000;
Shinchi et al, 2002). The benefit seen in the early combined-
modality trials was modest, however, with a median survival of
only 10 months. To improve the efficacy of the treatment, various
anticancer agents such as gemcitabine and radiation schedules are
being examined in clinical trials (Burris et al, 1997; Blackstock
et al, 1999; McGinn et al, 2001; de Lange et al, 2002; McGinn and
Zalupski, 2003; Okusaka et al, 2004). As yet, however, no regimen
has been shown to be superior to conventional chemoradiotherapy
with 5-FU. Thus, there is a need to develop new agents and
combination regimens to achieve greater survival benefit in
patients with unresectable advanced pancreatic cancer.
S-1 is a new oral fluoropyrimidine derivative consisting of tegafur
and two modulators, 5-chloro-2,4-dihydroxypyridine (CDHP) and
potassium oxonate in a molar ratio of 1:0.4:1 (Shirasaka et al,
1996). 5-Chloro-2,4-dihydroxypyridine is a reversible competitive
inhibitor of dihydropyrimidine dehydrogenase, which is an enzyme
for 5-FU degradation. Therefore, CDHP with tegafur is expected to
yield prolonged 5-FU concentrations in serum and tumour tissue.
Potassium oxonate is a reversible competitive inhibitor of orotate
phosphoribosyltransferase, which is an enzyme for 5-FU phosphor-
ibosylation in the gastrointestinal mucosa. It is reported that
potassium oxonate ameliorates the gastrointestinal toxicity of
tegafur by decreasing 5-fluorodeoxyuridine monophosphate pro-
duction in the gastrointestinal mucosa (Shirasaka et al, 1993).
Recent clinical trials of S-1 have shown promising results in various
solid tumours (Koizumi et al, 2000; Ohtsu et al, 2000; Kawahara
et al, 2001). In an early phase-II clinical study for metastatic
pancreatic cancer in Japan, the objective response rate of S-1 as a
single agent was 21.1% (4/19) (Ueno et al, 2005).
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sS-1 has also been shown to be a potent radiosensitizer in human
solid tumour xenograft (Fukushima et al, 1998; Harada et al, 2004),
which suggests that the combination of radiotherapy and S-1 may
improve survival in patients with locally advanced pancreatic
cancer. However, no previous reports have described the efficacy
and safety of chemoradiation therapy with S-1 for the treatment of
pancreatic cancer. Thus, we conducted a phase-I study to
determine the maximum-tolerated dose (MTD) and dose-limiting
toxicity (DLT) of S-1 and radiation combination therapy in
patients with unresectable pancreatic cancer.
PATIENTS AND METHODS
Eligibility
Patients with histologically or cytologically confirmed adenocarci-
noma of the pancreas were enrolled onto this study from July 2004
to December 2005 at the Kagoshima University Hospital. Eligible
patients were clinically or surgically staged and considered
unresectable for cure. Patients with metastatic disease were eligible
if the principal symptom associated with their primary disease was
pain and if they had an estimated life expectancy greater than 6
months. Eligibility criteria also included the following: age X20
years; Eastern Cooperative Oncology Group performance status of
0–2; measurable or assessable disease; life expectancy of 43
months; adequate organ function defined as granulocyte count of
X1500ml
–1, haemoglobin X8gdl
–1, platelet count X100000ml
–1,
bilirubin p1.5mgdl
–1, and creatinine p2.5mgdl
–1. If the
patients had any previous chemotherapy, radiotherapy or combined-
modality treatment for either advanced disease or postoperative
adjuvant therapy, that treatment had to have been discontinued
for at least 4 weeks before entry into the study.
The exclusion criteria were as follows: active infection, severe
heart disease, interstitial pneumonitis or pulmonary fibrosis,
pleural effusion or ascites, active gastroduodenal ulcer, pregnant
or lactating females, severe mental disorder, active concomitant
malignancy, and other serious medical conditions. The patients
who did not have sufficient integrity of the gastrointestinal tract
or who had malabsorption syndrome were also excluded. The
protocol was approved by the Human Studies Group at the
Kagoshima University School of Medicine. All patients gave
written informed consent before participation.
Treatment program
S-1 was supplied by Taiho Pharmaceutical Co. Ltd (Tokyo, Japan).
Each S-1 capsule contained 20 or 25mg of tegafur. Individual doses
were rounded as closely as possible to the calculated dose, given
the available formulation. The study drug was administered orally
in two divided doses after breakfast and supper at a dosage of 60 or
80mgm
–2day
–1. Patients were scheduled to receive S-1 at five
levels (1, 2, 3a, 3b, and 4), as listed in Table 1.
External-beam radiotherapy was delivered with 10MV photons
by using a conformal technique in fractions of 1.25Gy 2 per day,
5 days per week, totaling 50Gy per 40 fractions for 4 weeks. The
radiation field included the primary tumour and adjacent lymph
nodes (pancreaticoduodenal and celiac axis), as defined by
treatment-planning computed tomography (CTS-20 SPS, Shimadzu
Co. Kyoto, Japan) performed 1 or 2 days before treatment.
Toxicity and efficacy evaluation
Toxicity was graded according to the National Cancer Institute:
Common Toxicity Criteria version 2.0. The DLT was reached when
any of the following occurred: grade 3 leukocytopaenia and/or
neutropaenia with high fever, grade 4 haematologic toxicities, or
grade 3 or 4 nonhaematologic toxicity excluding nausea, vomiting,
anorexia and fatigue in the absence of appropriate antiemetics,
or grade 3 or 4 nausea/vomiting uncontrolled by aggressive
antiemetic support, or delay of recovery from treatment-related
toxicity for more than 2 weeks.
Standard antiemetic therapy was prescribed as required.
Antidiarrhoeal drugs were not given prophylactically but could
be used for the symptomatic treatment of diarrhoea of grade 2 or
higher. Chemotherapy was withheld upon development of a grade
2 or higher nonhaematologic toxicity or grade 3 or higher
haematologic toxicity, and resumed at the same dose level when
symptoms were grade 1 or when granulocyte and platelet counts
were 1500 and 100000ml
 1, respectively. Radiation could be held
for toxicity at the discretion of the treating physician.
At least three patients were enrolled at each dose level. If DLT
was observed in the initial three patients, a maximum of three
additional patients was entered into the same dose level. The MTD
was defined as the dose at which two or more patients developed
DLT.
Physical examinations, complete blood cell counts, and bio-
chemistry tests were performed at least once weekly. Tumour
assessment by computed tomography was performed every 3
months. Tumour responses were evaluated according to the World
Health Organization’s criteria (World Health Organization, 1980).
Serum CA19-9 concentrations were measured every 4 weeks. A
value of 37Uml
–1 was defined as the upper limit of normal.
Overall survival time was calculated from the date of treatment
initiation to the date of death or the last follow-up. Progression-
free survival time was calculated from the date of treatment
initiation until documented disease progression or death due to
any cause (whichever occurred first).
RESULTS
Patient characteristics
Between August 2004 and December 2005, 17 patients were
enrolled in the study: 10 men and seven women. The median age of
the participants was 66 years (range, 40–79 years). Patient
characteristics are summarised in Table 2. Eleven patients had
locally advanced unresectable disease without distant metastases,
and six patients had metastatic disease. Before the start of the
study, two patients had undergone gastrojejunostomy for duode-
nal obstruction, and nine had undergone biliary drainage for
obstructive jaundice. Ten patients had abdominal or back pain at
study entry. Patients were treated with S-1 and concurrent
radiation as listed in Table 1. The first patient developed DLT at
level 1. Next, three patients were entered at the same level. With no
further DLT demonstrated in these three consecutive patients, level
escalation proceeded. Four patients were initially enrolled at level 2
and no DLT was observed at this level. As a result, a total of four
patients were treated at both level 1 and level 2.
Toxicity and recommended dose
All 17 patients completed the combined S-1 and radiation therapy
and were evaluated for toxicity, as listed in Table 3. No treatment-
related deaths occurred during the study. Haematologic toxicity,
Table 1 S-1 Dose levels and schedule
Dose level n S-1 dose (mgm
 2) S-1 schedule
1 4 60 Days 1–7, 15–21
2 4 60 Days 1–14
3a 3 60 Days 1–21
3b 3 80 Days 1–21
4 3 80 Days 1–28
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sparticularly leukopaenia (Xgrade 1:35%), was a common effect of
combined S-1 and radiation therapy with this schedule of
administration. Gastrointestinal toxicity, such as anorexia
(Xgrade 1:53%) and nausea (Xgrade 1:35%), was also frequently
seen, but was usually mild and transient.
Three patients showed signs of DLT: one patient developed
grade 3 vomiting at the level 1 dose and one developed grade 3
anorexia at the level 4 dose. These patients quickly recovered with
7 days rest of chemoradiation. In addition, one patient developed
grade 4 neutropaenia at the level 4 dose; this was observed during
the last 5 days of treatment and resolved shortly after the
completion of treatment. No DLT was observed at the 2, 3a, and 3b
dose levels (Table 3). Because two of three patients receiving the
level 4 dose showed DLT, level 4 was considered the MTD, and
level 3b (80mgm
–2day
–1given on days 1–21) is proposed as the
recommended dose level for further studies with this schedule.
Efficacy
The objective tumour responses at each dose level are shown in
Table 4. Of the 17 enrolled patients, six patients (36%) had a PR, 10
(59%) had radiologically SD, and the other one patient (5%) had
PD. The serum CA19-9 concentration was reduced to less than 50%
of baseline values in 8 (50%) of 16 patients who had a pretreatment
value of more than the upper limit of normal (37Uml
–1). At the
time of analysis, 14 patients died because of disease progression.
The median overall survival was 12.3 months (range: 2.7–18.2
months) and the median disease-free survival was 7.0 months
(range: 1.2–14.5 months).
DISCUSSION
Concomitant radiotherapy and chemotherapy is commonly used
to treat locally unresectable pancreatic cancers (Moertel et al, 1969;
Gastrointestinal Tumour Study Group, 1981, 1988; Klaassen et al,
1985; Poen et al, 1999). 5-fluorouracil has been used for
chemoradiation because it can enhance the effects of radiation
(Whittington et al, 1995; Ishii et al, 1997). The novel oral
anticancer agent S-1 was developed to improve the tumor-selective
toxicity of 5-FU and has shown a good efficacy for a variety of solid
tumours, including pancreatic cancer (Koizumi et al, 2000; Ohtsu
et al, 2000; Kawahara et al, 2001; Ueno et al, 2005). Thus, S-1 may
also act as a radiosensitizer because it has cytotoxic mechanisms
similar to those of 5-FU (Hirata et al, 1999; Hoff et al, 2003;
Schoffski, 2004). Harada et al (2004) evaluated S-1 in combination
with ionising radiation both in vivo and in vitro against human
oral cancer cell lines. They showed that the combination of S-1 and
radiation was more effective than either agent alone, and that S-1
administration before radiation was more effective than adminis-
tration after radiation. As stated above, S-1 has also been shown to
be a potent radiosensitizer, which suggests that the combination of
radiotherapy and S-1 may improve survival in patients with locally
advanced pancreatic cancer. Thus, we performed a phase-I study
to evaluate the efficacy and safety of combined S-1 and radiation
therapy in patients with unresectable pancreatic cancer.
S-1 has already undergone phase I and phase II testing in several
solid tumours in Japan and Western countries (Koizumi et al,
2000; Ohtsu et al, 2000; van Groeningen et al, 2000; Kawahara et al,
2001; Hoff et al, 2003; Ueno et al, 2005; Nakamura et al, 2006). The
main adverse reaction was myelosuppression in a Japanese phase-I
study, and diarrhoea in a European and a North-American phase-I
study (van Groeningen et al, 2000; Hoff et al, 2003). It is well
known that total dose tolerated in Western populations when used
in the advanced settings is significantly less tolerated than in
Eastern populations. van Groeningen et al (2000) have reported
that this might be due to the polymorphism of cytochrome P450,
with differences in activity among patients with different ethnic
backgrounds. They have also reported that cytochrome P450
seemed to be involved in the conversion of tegafur into 5-FU,
resulting in higher 5-FU levels in Western populations (van
Groeningen et al, 2000). In Japan, the standard single-agent dose is
80mgm
–2day
–1 twice daily for 28 consecutive days, followed by
14 days of rest, although the RD of S-1 was 70–80mgm
–2 in
Europe, and 60mgm
–2in the US. In the present phase-I study, we
have examined the appropriate dose and duration of S-1 and the
safety of S-1 with radiation therapy. The dosage was escalated from
60mgm
–2day
–1at level 1–3a to 80mgm
–2day
–1at levels 3b and
4, respectively. In addition, S-1 was administered for 14 days in
levels 1 and 2, for 21 consecutive days in level 3, and for 28
Table 2 Patient characteristics
Characteristics No. of patients (%)
Patients enrolled 17
Gender
Men 10 (59)
Women 7 (41)
Age (years)
Median (range) 66 (40–79)
ECOG performance status
0 8 (47)
1 7 (41)
2 2 (12)
Tumour location
Head 12 (71)
Body tail 5 (29)
Stage of disease
Locally advanced alone 11 (65)
Locally advanced and metastatic 6 (35)
Sites of metastatic disease
Liver 1 (6)
Distant lymph nodes 5 (29)
ECOG¼Eastern Cooperative Oncology Group.
Table 3 Grade 3 or higher toxicities
Level
1( n¼4) 2 (n¼4) 3a (n¼3) 3b (n¼3) 4 (n¼3)
Toxicity grade
a 34343 4 3 434
Neutropaenia 0 0 0 0 0 0 0 0 0 1
Vomiting 1 0 0 0 0 0 0 0 0 0
Anorexia 0 0 0 0 0 0 0 0 1 0
aCI¼Common Toxicity Criteria, version 2.0.
Table 4 Objective tumour response
Response
Dose level n CR PR s.d. PD Response rate (%)
14 0 1 2 1 2 5
24 0 1 3 0 2 5
3a 3 0 1 2 0 33
3b 3 0 2 1 0 67
43 0 1 2 0 3 3
Total 17 0 6 10 1 35
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sconsecutive days in level 4. Dose-limiting toxicity was observed in
two of three patients at level 4, which was defined as the MTD. No
unexpected or life-threatening toxicities were observed during the
study. Consequently, the recommended dose of S-1 combined
with radiation was the level 3b dose: 80mgm
–2day
–1 given on
days 1–21.
The combination of S-1 and radiation showed a good objective
response rate of 35% (6/17), with a good tumour growth control
rate (PR plus SD) of 94% (16/17). Two (67%) of three patients at
level 3b, which was considered the recommended dose, obtained
PR, which suggests promising antitumour efficacy at this dose
schedule. Moreover, the serum CA19-9 level was reduced more
than 50% in 8 (50%) of 16 patients with an abnormal pretreatment
level. These results are encouraging and comparable to those of
patients treated with chemoradiation at other treatment schedules
(Gastrointestinal Tumour Study Group, 1981, 1988; Klaassen et al,
1985; Blackstock et al, 1999; McGinn et al, 2001; de Lange et al,
2002; Shinchi et al, 2002; McGinn and Zalupski, 2003; Okusaka
et al, 2004).
In patients with locally advanced pancreatic cancer treated with
chemoradiation it is important to enhance local tumour control
and simultaneously reduce the risk of distant metastases. S-1 not
only has an ability of local disease control as a potent radio-
sensitizer but also has systemic effects as a chemotherapeutic agent
(Schoffski, 2004). Thus, S-1 with radiation may result in improved
long-term survival in chemoradiation treated patients. Moreover,
because S-1 is administered orally, this combination therapy is
quite feasible in the outpatient treatment setting without
hospitalisation. The ability of S-1 to deliver protracted plasma
concentrations of 5-FU without the need for intravenous access or
an infusion pump makes it an attractive alternative in regimens
combining chemotherapy and radiation.
In conclusion, our combination regimen of S-1 and radiation is
a promising and well-tolerated approach with possible application
at an outpatient clinic. S-1 at a dosage of 80mgm
–2day
–1given on
days 1–21 is safe and recommended for further studies when given
with EBRT. Phase-II study of this regimen is underway in patients
with locally advanced and unresectable pancreatic cancer.
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